Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Zai Lab Enters $1.4 Billion Deal with MacroGenics for Four Immunoncology Drugs

publication date: Jun 16, 2021

Shanghai's Zai Lab announced a four-drug immunonocology deal with MacroGenics worth over $1.4 billion. Both companies will contribute IP to the products. Zai Lab will have Asian and/or global rights for up to four CD3- or CD47-based bispecific molecules from Macrogenics, plus Zai will have rights to MacroGenics' DART® and TRIDENT® multi-specific platforms. In return, Zai will provide MacroGenics with rights to specific CD47 IP for select tumor targets. Zai will make an upfront payment of $25 million and an investment of $30 million in MacroGenics, plus up to $1.4 billion in milestone payments. More details....

Stock Symbols: (NSDQ: ZLAB; HK: 9688) (NSDQ: MGNX)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.